Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review
C Wang, Y Zhang, W Chen, Y Wang, D Xing - Biochimica et Biophysica …, 2023 - Elsevier
Epidermal growth factor receptor (EGFR), a transmembrane glycoprotein that mediates
cellular signaling pathways involved in cell proliferation, angiogenesis, apoptosis, and …
cellular signaling pathways involved in cell proliferation, angiogenesis, apoptosis, and …
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
P Li, B Li, N Yang, T Xu, Z Zheng - Expert Opinion on Therapeutic …, 2023 - Taylor & Francis
Introduction Abnormal expression of epidermal growth factor receptor (EGFR) contributes to
tumor development, especially in non-small cell lung cancer (NSCLC). Although multiple …
tumor development, especially in non-small cell lung cancer (NSCLC). Although multiple …
A partial epithelial‐mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction
GA Pastorino, I Sheraj, K Huebner… - The Journal of …, 2024 - Wiley Online Library
Partial epithelial‐mesenchymal transition (p‐EMT) has recently been identified as a hybrid
state consisting of cells with both epithelial and mesenchymal characteristics and is …
state consisting of cells with both epithelial and mesenchymal characteristics and is …
[HTML][HTML] Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer
V Sakanyan, N Iradyan, R Alves de Sousa - BioTech, 2023 - mdpi.com
Targeted protein degradation is an attractive technology for cancer treatment due to its
ability to overcome the unpredictability of the small molecule inhibitors that cause resistance …
ability to overcome the unpredictability of the small molecule inhibitors that cause resistance …
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation
Y Zhu, X Ye, Y Wu, H Shen, Z Cai, F Xia… - Journal of Medicinal …, 2024 - ACS Publications
The epidermal growth factor receptor (EGFR) tertiary C797S mutation is an important cause
of resistance to Osimertinib, which seriously hinders the clinical application of Osimertinib …
of resistance to Osimertinib, which seriously hinders the clinical application of Osimertinib …
Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo
X Pang, D Cui, B Lv, CY Wang - Journal of Medicinal Chemistry, 2024 - ACS Publications
Directly targeted KRAS inhibitors are now facing resistance problems, which might be
partially solved by the combination of SOS1 inhibitors with KRAS inhibitors. However, this …
partially solved by the combination of SOS1 inhibitors with KRAS inhibitors. However, this …
Exploring the structural activity relationship of the osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small …
The USFDA granted regular approval to Osimertinib (AZD9291) on March 30, 2017, for
treating individuals with metastatic Non-Small Cell Lung Cancer having EGFR T790M …
treating individuals with metastatic Non-Small Cell Lung Cancer having EGFR T790M …
Transforming Cancer Care: Immunotherapy with Advanced Drug Delivery
S Srivastava, TC Siang, D Kaliyappan… - Journal of Drug Delivery …, 2024 - Elsevier
This study investigates the integration of immunotherapeutic agents into various drug
delivery platforms for cancer treatment, emphasizing their efficacy in diverse cancer types …
delivery platforms for cancer treatment, emphasizing their efficacy in diverse cancer types …
Design, Synthesis, and Anticancer Evaluation of Hemithioindigos via Inhibition of Human Topoisomerases
Hemithioindigos were designed as topoisomerase inhibitors, synthesized, and evaluated for
their anticancer properties against lung (A549) and breast (MDA‐MB‐468 and MCF7) …
their anticancer properties against lung (A549) and breast (MDA‐MB‐468 and MCF7) …
In silico construction and evaluation of anti-EGFR ScFv and IFN-β fusion protein as a novel immunocytokine for the treatment of HER1 positive breast cancer
MI Khan, M Hassan, A Sohail, N Ahmad, I Khan… - 2023 - researchsquare.com
Context Human epidermal growth factor receptor 1 (HER1) positive breast cancer is
characterized by overexpression of the HER1 receptor protein on cancer cells leading to …
characterized by overexpression of the HER1 receptor protein on cancer cells leading to …